BARICITINIB VERSUS TOCILIZUMAB FOR THE TREATMENT OF MODERATE TO SEVERE COVID-19

被引：0
|
作者：
Lewis-Wolfson, Temeka [1 ]
Joyner, Kayla [2 ]
Reid, Nancy [1 ]
机构：
[1] Winchester Med Ctr, Winchester, VA USA
[2] Shenandoah Univ, Bernard J Dunn Sch Pharm, Winchester, VA USA
来源：
CRITICAL CARE MEDICINE | 2023年 / 51卷 / 01期
关键词：
D O I：
暂无
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
409
引用
收藏
页码：191 / 191
页数：1
相关论文
共 50 条
  • [21] Effect of tocilizumab versus standard of care in adults hospitalized with moderate-severe COVID-19 pneumonia
    Aomar-Millan, Ismael F.
    Salcaterra, Juan
    Alvarez, Enrique Raya
    MEDICINA CLINICA, 2022, 159 (08): : E54 - E54
  • [22] Effect of tocilizumab versus standard of care in adults hospitalized with moderate-severe COVID-19 pneumonia
    Cardona-Pascual, Ignacio
    Berlana, David
    Martinez-Valle, Ferran
    Campany-Herrero, David
    Bruno Montoro-Ronsano, Jose
    MEDICINA CLINICA, 2022, 158 (07): : 301 - 307
  • [23] Comparative Efficacy of Tocilizumab and Baricitinib Administration in COVID-19 Treatment: A Retrospective Cohort Study
    Kojima, Yuichi
    Nakakubo, Sho
    Takei, Nozomu
    Kamada, Keisuke
    Yamashita, Yu
    Nakamura, Junichi
    Matsumoto, Munehiro
    Horii, Hiroshi
    Sato, Kazuki
    Shima, Hideki
    Suzuki, Masaru
    Konno, Satoshi
    MEDICINA-LITHUANIA, 2022, 58 (04):
  • [24] Tocilizumab for severe COVID-19 pneumonia
    Piano, Salvatore
    Vettor, Roberto
    Angeli, Paolo
    LANCET RHEUMATOLOGY, 2020, 2 (11): : E659 - E660
  • [25] Comments on “Baricitinib versus tocilizumab in mechanically ventilated patients with COVID-19: a nationwide cohort study”
    Rong Li
    JuanJuan Wang
    Qian Li
    QianYue Guo
    Jun Kang Zhao
    James Cheng-Chung Wei
    Li-Yun Zhang
    Critical Care, 28 (1):
  • [26] Commenting on baricitinib versus tocilizumab in mechanically ventilated patients with COVID-19: a nationwide cohort study
    James Cheng Chung Wei
    Poi Kuo
    Po-Cheng Shih
    Critical Care, 28 (1):
  • [27] Tocilizumab use in patients with moderate to severe COVID-19: A retrospective cohort study
    Chilimuri, Sridhar
    Sun, Haozhe
    Alemam, Ahmed
    Kang, Kyoung-Sil
    Lao, Peter
    Mantri, Nikhitha
    Schiller, Lawrence
    Sharabun, Myroslava
    Shehi, Elona
    Tejada, Jairo
    Yugay, Alla
    Nayudu, Suresh Kumar
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2021, 46 (02) : 440 - 446
  • [28] Why tocilizumab could be an effective treatment for severe COVID-19?
    Binqing Fu
    Xiaoling Xu
    Haiming Wei
    Journal of Translational Medicine, 18
  • [29] Predictors of the Outcomes Following the Tocilizumab Treatment for Severe COVID-19
    Singla, Karan
    Puri, Goverdhan D.
    Niyogi, Subhrashis Guha
    Mahajan, Varun
    Kajal, Kamal
    Bhalla, Ashish
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2022, 14 (08)
  • [30] Why tocilizumab could be an effective treatment for severe COVID-19?
    Fu, Binqing
    Xu, Xiaoling
    Wei, Haiming
    JOURNAL OF TRANSLATIONAL MEDICINE, 2020, 18 (01)
12345